AWX (Avalon Holdings) : A Deep Asset Value Discount as Operations Turn Profitable

 Investment Summary

Avalon Holdings (AWX) is an overlooked, tiny, and illiquid microcap. AWX trades at $2.75 versus my base-case NAV of $8.40, while a stressed SOTP still produces $3.53 per share. It owns a profitable waste management business and has substantial tangible assets. The balance sheet includes approximately $60.9 million of PP&E and $4.8 million, or $1.23 per share, of cash. The company's balance sheet also includes $33.0 million in debt and lease obligations, or $8.47 per share, and $51.1 million in total liabilities. The waste business is valued before debt. Therefore, I subtract AWX’s debt and finance leases from the total company value. I do not subtract normal operating liabilities, such as accounts payable, because they are already reflected in the operating business value.

AWX trades below book value, but that's not the only thesis. Avalon is a waste management operator with a portfolio of golf, resort, and recreational properties. AWX is a better value if you separate the operating business from real estate. Consolidated earnings obscure this distinction.

The second part of the investment thesis is improving operations. Q2 2026 revenue increased to $20.9 million from $20.3 million. Net income increased to $0.9 million, or $0.23 per share, from $0.3 million, or $0.07 per share, a year earlier. This is critical. If profitability persists, shareholders may no longer need asset sales to realize value

At $2.75, AWX trades at a substantial discount to my estimate of the combined value of those assets and operations. The thesis does not require full NAV recognition. It requires only sustainable operating profitability and asset values materially above the current equity market value.

Company Overview

Avalon Holdings operates two businesses, waste management and golf operations. The waste segment provides waste management and disposal services to commercial and industrial customers and generates most of Avalon's revenue.

The golf and related segment owns and operates The Grand Resort, golf courses, country clubs, and recreational facilities, primarily in Ohio and Pennsylvania. These operations contain substantial land, buildings, upgrades, and improvements.

That combination makes AWX interesting. The waste business should be valued primarily on its earnings and cash generation. Real estate should be valued based more on its intrinsic value.

Why the market may be wrong

AWX is easy to ignore. It is tiny, illiquid, insider controlled, lacks Wall Street coverage, and has inconsistent operational performance. Its golf and resort investments continue to consume substantial capital.

First, AWX owns a valuable collection of tangible assets. Second, its operating performance is improving. Avalon is valued largely on its historical weaknesses. At $2.75, the market assigns a substantial discount to both the property portfolio and the recent improvement in profitability. AWX does not need to trade at the full fair market value of its properties. With AWX at $2.75, even partial recognition of the underlying asset value materially changes the valuation.

Hidden Asset Value

Valuing AWX solely on consolidated earnings obscures the value of its underlying real estate

I separate AWX into three pieces:

I estimate AWX’s gross fair market value at approximately $61 million, or $15.64 per share. After deducting debt and finance leases and adding cash, the equity's fair value is approximately $32.8 million, or $8.40 per share.

I did not subtract the full $51.14 million in liabilities from the SOTP. This is because normal operating liabilities, such as accounts payable and deferred membership revenue, are already reflected in the going concern valuation. This produces a clean base NAV of $8.40 per share, compared with the current $2.75 price

Real Estate: ~ $40 million

AWX's real estate is the most difficult and important part of valuation.

AWX reported $60.9 million in gross PP&E, but the accounting value does not match the fair market value. I therefore value the major properties individually rather than relying on reported PP&E, since buildings depreciate over time. Land and property are not recorded at higher values when their market value increases. See below, where I value the major properties individually to estimate the $40 million. 

The Grand Resort  FMV = ~ $11–13 Million

The Grand Resort is Avalon's most valuable hidden asset. Avalon purchased the resort in 2014 for $3.1 million and completed substantial multi-year renovations. The resort includes 132 rooms and suites, approximately 146,000 square feet of hotel space, and 9.3 acres. It offers pools, restaurants, banquet facilities, a spa, fitness facilities, and other amenities. Based on comparable hotel transactions, prices range from $90,000 to $150,000 per room. I used only $11–13 million to account for AWX's location, property-specific characteristics, and valuation uncertainty. Avalon Lakes Golf Course and other real estate are not included in this estimate. Improving operations also support the valuation with growing room revenue. And the golf and resort segment has improved from a loss in the first half of 2025 to breakeven in the first half of 2026. At AWX’s $2.75 share price. The Grand Resort alone could be worth more than the company’s current equity market value. However, you must subtract the company's debt and other liabilities to calculate its net asset value.

Avalon Lakes and Headquarters FMV = ~$8-10 Million

Avalon Lakes and AWX's headquarters could be worth $8-10 million. Avalon Lakes is an 18-hole Pete Dye-designed championship golf course on 200 acres. It also has a 22,400-square-foot restaurant and maintenance building.

I estimate the golf property at $6 million. Also, AWX owns a restaurant, pro shop, medical spa, and dermatology center on 5.6 acres. I value the property at approximately $3 million. Together, the properties have a projected value of $9 million. The FMV estimate considers land acreage, the replacement cost of the golf course and clubhouse, comparable golf course transactions, and the value of the headquarters building and land.

Avalon at Buhl Park = ~$6–7 Million

The Avalon at Buhl Park could be worth $6-7 million. AWX owns the 18-hole golf course on roughly 130 acres, with 80,000 square feet of clubhouse and recreational facilities. These facilities include dining and banquet space, a pool, a fitness center, a spa, and a pro shop. Avalon acquired the property for $1 million in 2006. It invested $12 million in improvements. This is a large investment in the property. I estimate a conservative fair value of approximately $6.5 million, or $1.67 per share.

Based on real estate/comparable sales, Avalon at Buhl Park has an FMV of $6-7 million. My $6–7 million FMV estimate considers land, golf course, clubhouse, and other improvements, along with comparable golf-course and real-estate transactions in western Pennsylvania.

Avalon Field Club at New Castle FMV = ~ $6–7 Million

Avalon Field Club at New Castle could be worth $6-7 million. In addition to the 18-hole golf course, AWX owns a 20,000-square-foot clubhouse with dining, banquet, and pro-shop facilities. Assuming $800,000 of debt, AWX acquired the financially distressed property in 2019. More than $6 million was invested in the course, clubhouse, and grounds. Based on land owned, renovated facilities, and recent golf course transactions, I estimate a conservative fair value of $6.5 million, or $1.67 per share.

Boardman, Squaw Creek and Other Property FMV = ~ $4–6 Million

The Boardman athletic facility contains roughly 55,000 square feet on 3.5 acres. I estimate it at $2–3 million. Boardman was purchased for $1.3M in 2018 and has undergone substantial renovations. Squaw Creek was leased in 2003, with more than $6.90M in leasehold improvements.

Squaw Creek must be handled differently. Avalon operates the property under a long-term lease rather than owning the underlying acreage. I therefore assign value only to Avalon's leasehold interest and improvements rather than pretending it owns real estate.

Using the approximate midpoint of these property-level estimates produces a total real estate value of roughly $39–40 million. I rounded up to $40 million in the SOTP. 

Waste Management FMV= ~ $22- 24 million

The waste business may be AWX's best operating asset. In 2025, waste-management revenue was approximately $46 million, with $4.6 million of income. Capital expenditures were only about $145,000.

AWX's business is small, has customer-concentration risk, and includes event driven work.

AWX’s waste management business could be worth $22-24 million. The business is profitable, requires little capital investment, and generated about $46 million in revenue and $4.6 million in income in 2025. Results improved in the first half of 2026. Revenue increased 11% to $21.6 million, and income rose to $2.2 million. To add a margin of safety, I use $18 million in my base-case to reflect annual earnings of roughly $4.5–5.0 million.

The Operating Turnaround Matters

AWX deserves an uncertain valuation. Earnings and free cash flow are inconsistent. The company has invested substantial capital in golf and resort assets.

Q2 2026 revenue was $20.9 million, while net income reached $0.9 million, or $0.23 per share. This is versus $0.3 million and $0.07 a year earlier. One quarter does not signal a turnaround. However, AWX does not need rapid growth for its thesis to work. It needs sustainable profitability and cash generation.

If the waste business continues to produce profits and the golf/resort operations stop consuming excessive capital, AWX could generate cash to reduce debt. This would shift AWX from a traditional value trap to cheap assets with improving operations.

Balance Sheet

Q2 2026 provides evidence that operating economics may be improving. However, AWX still has approximately $51.14 million of total liabilities, including $18.11 million of current liabilities. Those figures are significant when assessing financial risk, but total liabilities shouldn't simply be subtracted from the sum of the part valuations.

If normal operating liabilities are already necessary to produce the earnings used to value the waste business, subtracting those liabilities again can understate equity value. Debt remains a risk. AWX needs enough operating cash flow to fund maintenance capital expenditures, pay interest, and eventually reduce leverage.

Book Value Is a Check

AWX's reported book value has historically been far above its stock price. Shareholders' equity is $36 million, or $9.36 per share, as of 09/21/26.

Some long-held real estate could be worth more than its carrying value. But specialized golf and resort properties could also sell below their accounting value. Capital expenditures do not necessarily create equivalent resale value.

Book value therefore provides a useful check. Property level valuation is the stronger argument.

Why Does the Opportunity Exist?

AWX's low price is no mystery. It is a tiny and illiquid micro-cap with no analyst coverage. It combines unrelated businesses that require different valuation methods. Historical earnings are inconsistent. Debt is meaningful. Insiders have substantial control, and outside shareholders have limited ability to force asset sales, buybacks, or other value-unlocking transactions.

Most importantly, no deadline forces management to monetize real estate. These are legitimate reasons for AWX to trade below NAV.

Management, Control and Capital Allocation

Management is both part of the thesis and a risk.

Chairman and CEO Ronald Klingle has led Avalon for decades and has substantial voting influence. Minority shareholders have limited control over strategy changes.

Capital allocation has been mixed. Management's large investments in golf, resort and recreational assets have created the tangible asset base underlying this thesis. However, those investments have not consistently generated attractive free cash flow.

The thesis therefore does not assume near term liquidation, an aggressive buyback, or property sale. But instead continued profitability, disciplined capex, and gradual debt reduction could help narrow the discount to NAV.

The base case matters most. It values real estate at around $40 million, waste operations at $18 million, and other assets at $3 million. After subtracting debt and finance leases and adding unrestricted cash, I estimate approximately $8.40 per share of equity value.

At $2.75, AWX trades at roughly one-third of that estimate.

More importantly, the bear case provides an appropriate test. Cut the real estate value by 25%, reduce the waste business to $12 million, assign zero to other assets, and the resulting value is still approximately $3.53 per share.

Margin of Safety

The margin of safety comes from conservative valuation assumptions, not from AWX's reported PP&E. In my base-case SOTP, I valued the properties individually at about $40 million. I value the waste business at only $18 million, even though it could be worth $22–24 million. $18M / $4.5M = 4.0× or $18M / $5.0M = 3.6×. My $18 million base-case value represents only about 3.6–4.0× earnings of $4.5–5.0 million. I assign just $3 million to other assets.

More importantly, the thesis holds up under substantial valuation cuts. Reducing real estate to $30 million, the waste business to $12 million, and other assets to zero still produces an estimated equity value of approximately $3.53 per share. That remains above the current stock price of $2.75. Downside protection is not absolute, and the current price provides room for several of my assumptions to be wrong.

Catalysts

AWX does not need a takeover or liquidation to see its price rise. The key catalyst is continued profitability. Sustained margins in the Waste business and better golf/resort operations should increase EBITDA and cash flow. Free cash flow could be used to reduce debt, transferring enterprise value to equity holders.

Property sales could be more dramatic because a transaction would provide evidence of real estate's actual market value. Other possible catalysts include lower capital spending, refinancing, non-core asset sales, and share repurchases at a large discount to NAV.

None is necessary for the base thesis. But any could shorten the market's recognition of fair value.

Risks

Golf and resort properties require capital. Continued heavy spending without adequate returns could consume the asset value supporting the thesis. Debt increases this risk because interest and refinancing reduce financial flexibility.

The $40 million real-estate valuation could also be wrong. Golf courses and specialized recreational properties are illiquid, location dependent, and difficult to value. A property can cost millions to improve without adding incremental value for another buyer.

Waste business carries a risk of customer concentration. And Q2's profitability may be temporary. Finally, insider control means minority shareholders cannot force management to sell assets, reduce debt, or repurchase shares. The discount could therefore persist for years.

What can lead to a wrong thesis?

Declining revenues, margins, and negative cash generation in the waste business would reduce my $18 million fair value estimate. Poor capital allocation, including significant dilution, excessive borrowing, or continued investment in low-return, capital-intensive projects, would also weaken the thesis. Evidence that the real estate is worth materially less than my $40 million estimate would also weaken the asset-value thesis

Conclusion

My base-case SOTP is $40 million for real estate, $18 million for the waste business, and $3 million for other assets. After subtracting $33.02 million of debt and finance leases and adding $4.795 million of cash, I estimate equity value at approximately $8.40 per share. I still get $3.53 per share after cutting the property valuation to $30 million, reducing the waste valuation to $12 million, and assigning nothing to other assets.

$40M real estate + $18M waste + $3M other − $33.02M debt/leases + $4.795M cash = ~$32.8M equity value = ~$8.40/share.

$2.75 stock price → $8.40 base NAV → $3.53 stressed NAV. 

Long AWX

Innovative Food (IVFH) Update

Innovative Food (IVFH ) Q2 2026 results are better than headline numbers suggest. Bottom line is a dramatic balance sheet transformation, lower costs, continued profitability, and hidden operating leverage. Q2 2026 revenue fell 21.5% to $13.1 million, yet it remained profitable, earning $366,000. IVFH is a tiny (13M market cap), simple, and financially strong company: Cash = $1.8 million; $6.6 million in net working capital. Net working capital equals roughly $0.13 per share, compared with a stock price of $0.23. Management created operating leverage by closing underperforming businesses, reducing debt, and lowering costs. The risks are persistent revenue decline and customer concentration. The key question is whether the recent sales decline shows a permanent deterioration or a temporary disruption due to restructuring and industry pressures.

Innovative Food Holdings: Reports Financial Results for Second Quarter of 2026

Investment thesis

Innovative Food Holdings is a tiny specialty-food distributor undergoing major restructuring that the market missed.

The headline numbers look bad. Q2 2026 revenue fell 21.5% to $13.1 million. Yet IVFH remained profitable, improved gross margin, cut operating expenses, exited an unprofitable business, sold non-core real estate, and used the proceeds to virtually eliminate its debt.

The result is a much simpler company with $1.8 million in cash, $250,000 in debt, $6.6 million in net working capital, and a profitable business.

The thesis does not require strong growth. If revenue stabilizes while management maintains the revised cost structure, I believe the fair value is closer to $0.40 per share. If revenue returns to modest growth and operating leverage appears, a price greater than .40 is reasonable.

The central question is simple: Has IVFH become a permanently shrinking business, or has management created a smaller, cleaner company capable of producing substantially better margins?

Exiting business matters

One of the most important parts of the thesis is the elimination of its retail specialty cheese business. During the first six months of 2025, these discontinued operations generated approximately $7.8 million in revenue, but only $721,000 in gross profit and a $1.45 million loss.

Management sold the Pennsylvania property associated with those operations. This was the right capital allocation decision. Rather than protecting low quality revenue to maintain reported sales. Management eliminated the loss-making operation, monetized real estate, and repaired the balance sheet. IVFH received approximately $8.8 million from the sale of its Pennsylvania property and used it to repay debt and finance leases.

Risks

IVFH’s biggest risk is its declining revenue. Quarter 2 2026 revenues fell 21.5% year over year.
 And cost cuts are unlikely to support profits if sales continue to fall. Customer concentration is also high. U.S. Foods and Gate Gourmet account for about 58% of quarterly revenue, making the loss of these customers significant. The company also faces increased online competition, lower volumes, and pricing pressure. Because margins remain thin, even a small decline in gross profit materially hurts earnings. Finally, IVFH is a small OTC traded company with limited liquidity. The investment thesis ultimately depends on management controlling costs while stabilizing revenue.

Catalyst

Revenue stabilization.

IVFH is a SPECULATIVE buy

Innovative Food Holdings (IVFH) Update: The Activist Investor Thesis

Update 07/14/2026

The updated 13G language, effective 07/14/2026, is critical. Harper says share ownership did not change between December 31 and March 31. This suggests that the additional 878,489 shares were accumulated after March 31. Meaning it was during Q2 2026 (April–June) rather than Q1.

If that's correct. It's notable. Because Harper was added aggressively after management changes and operational turnaround efforts were underway. That timing strengthens the case that Harper's purchases reflect her conviction in the turnaround rather than just a passive position increase. It also means that the estimated average purchase price should be based on Q2 2026 trading, not Q1. This is a revision to previous comments.

Update 07/10/2026

Harper Asset Management reported a 6.90% ownership with an amended 13G. During Q1 2026, Harper acquired an additional 878,489 shares. This increased their ownership from 5.2% (2,869,541 shares) reported on February 3, 2026, to 6.9%. Based on the timing of the purchases, Harper's estimated average purchase price was approximately $0.42-$0.44 per share. July 10, 2026, IVFH price per share was .26.

IVFH is a SPECULATIVE opportunity. The nano cap is led by a shareholder aligned management team and board with substantial skin in the game.

Innovative Food Holdings enters Q1 2026 as a different company. After disappointing Q4 2025 results, the board forced the CEO's resignation and completed the Pennsylvania warehouse sale. As a result, IVFH has changed leadership and is an asset-light operation. The balance sheet is now clean following the sale of its Pennsylvania facility and the closure of its cheese business. These changes have created a focused and simplified company.

Management said the online demand isn't broken. Integration, ERP, onboarding, and platform transitions are current weaknesses. Although management believes sales will recover after modernization. However, the turnaround works only if management stabilizes revenue growth and improves margins.

IVFH is a long shot! But if the company maintains or increases margins and is consistently profitable. Innovative Food Holdings becomes a more valuable company.

Risks

A few customers make up most of the revenue. US Foods accounts for 37% of revenue, Gate Gourmet 14%, and Sam's Club 12%. Two-thirds of total sales come from these three customers. Single customer accounts for 23% of receivables. And, management revealed that it relies on a major distributor.

The turnaround is still a question. Although the remaining high-margin platform has the potential to grow revenue organically. Liquidity has improved, but cash is only $1.23M. IVFH is now financially clean but not debt-free. The company still carries liabilities, including leases, separation costs, and acquisition debt.

Liquidity is tight, with only ~1 million in cash. Also, management is working to address fragmented systems, manual processes, integration, forecasting, procurement, and service. Management believes fixing these problems may take longer than expected. Loss of a major customer will materially impact their results. 

The company made material changes in a short period. This includes management shifts, acquisitions, business closures, and major asset sales. While these actions improve the business over time. They also increase execution risk. 

Financial reporting and IT controls had material weaknesses. This is not a major threat. But it raises concerns about the reliability of financial reporting, which management must address.

Food distribution is a highly competitive business. And the IVFH operates with gross margins of about 26%, which leaves limited room for error. Operations have low margins, and rising freight and transportation costs. Even small operational mistakes impact profitability.

The company's CFO (Gary Schubert) was promoted to CEO in December 2025 after the CEO's removal. And the search for a replacement CFO is still ongoing. These management changes may be positive.

As a result, the risk of major financial distress is lower than in the past. However, risks remain. Cash generation is still limited. Future acquisitions will require additional financing. The company's cash flow can be volatile, with large potential losses due to its high customer concentration.

Opportunities:

IVFH has developed relationships with hundreds of specialty food producers over the past 27 years. Niche food companies are too small and specialized to sell to these large distributors. So, IVFH distributes these vendors' products using its technology platform, including onboarding, integration, and listing. IVFH lists these specialty items with the large foodservice distributors. Distributors add them to their ordering systems so that chefs and restaurants can place orders.

A chef/restaurant places an order through one of the largest distributors. The order is routed in real time via IVFH's platform to the vendor. IVFH handles vendor agreements, rebates, and administrative tasks. Small producers can't handle it. The product is drop shipped directly to the customer, bypassing the distribution center. IVFH's growth doesn't come from building inventory facilities or buying trucks. It comes from adding more vendors and items. No more inventory risk with higher margins than traditional storage fulfillment. Fast, fresh delivery of unique items that large distributors don't stock themselves. Network effects include more vendors, distributors, and chef orders as more vendors join.

IVFH's dropship digital channel connects artisan producers with major distributors and chefs with no inventory required. This makes IVFH's business highly scalable. It has very low capital and operating expense requirements in comparison to traditional distribution.

Management discussed the time to onboard new specialty food vendors. This used to take 6–12 months, limiting growth. Although they have added AI, staff, and improved processes. If successful, this will significantly speed up onboarding and enhance revenue growth.

Execution and expansion of existing opportunities were the messages of the Q1 2026 conference call. Also, compared to Q4 2025, ERP updates, process improvements, AI, and cash preservation were discussed.

Total liabilities fell from $13.3M to $4.0M quarter-on-quarter. Operating income rose to $350K, up from last year's $260K, despite a 19% revenue decline. The company is now simple and profitable with an improved balance sheet.

The company's value increases substantially if revenue and margins remain consistent in its niche food distribution business. However, if revenue continues to decline, fair value will likely move closer to the tangible book value of .13.

Q1 2026 Sales were down 19%. But they still made a greater profit than in the prior-year period, with margins improving to 26%. Systems must be modernized, and revenue must be maintained. Earnings power could be substantially higher than current results suggest. The stock price should be significantly higher than the current price of .29.

The revenue decline was due to the company's exit from the retail cheese business. Although Q1 2026 operating income increased. This despite a 19% decline in revenue. IVFH is sacrificing lower-quality revenue while improving the economics of the remaining business. US Foods' sales must stabilize to support a higher stock price. Revenue can improve through better customer onboarding and a narrower focus.

IVFH is heavily influenced by activist investors and economically aligned with shareholders. The board and small-value hedge funds have an outsized influence over the company, owning most of the outstanding shares. Their average share price paid is nearly + twice the current price. They are not selling.

The upside is substantial at the current price for speculative investors willing to gamble on a turnaround. IVFH has completed the company's financial restructuring.

Ownership, Incentives, and Board Alignment

Innovation Food has an advantage with its ownership.

Officers and directors own approximately 46.9% of IVFH. That is unusually high. It creates strong alignment among management, the board, and external shareholders. Microcap executives often prosper regardless of stock performance. But IVFH’s leadership team is directly tied to IVFH's price.

Chairman James Pappas owns 19.1% of the company. Pappas is not a food industry executive. Instead, he has an investment banking background in mergers and acquisitions, as well as corporate governance. Papas did activism at Jamba, The Pantry, U.S. Geothermal, and Morgan's Foods. They were sold. He worked in leveraged finance, recapitalizations, and corporate transactions at Goldman Sachs and Bank of America.

His background is relevant. Because many of IVFH's actions over the last two years resemble an activist playbook. The success of these steps remains to be seen. However, they suggest a board focused on improving intrinsic value rather than preserving the status quo.

Director Denver Smith is a hedge fund manager and CFA. His investment group owns 9% of the company. And his investment background adds to capital allocation decisions and fiscal oversight.

The board is further strengthened by Mark Schmulen. An entrepreneur and investor with experience in venture-backed technology businesses, digital marketing, and private investing. While IVFH is not a technology company, Schmulen brings an important perspective. This is valuable as the company proceeds to develop its ecommerce and customer acquisition capabilities.

CEO Gary Schubert worked at Walmart for 15 years and at Tyson Foods for 3 years. His background includes business transformation, merchandising, finance, and ecommerce strategy.

IVFH's board combines activist investors, experienced capital allocators, entrepreneurs, and operators. The combination is overlooked. Although the company still confronts significant business risks. The people responsible have financial incentives and the professional experience to execute.

Management’s Compensation

Executive compensation supports shareholders. CEO Gary Schubert's long-term compensation is heavily tied to stock performance.

Executive equity awards vest if IVFH's stock price increases severalfold. Schubert's has stock price targets ranging from $2.45 to $4.08. Approximately 3.5 million shares of awards are tied to executive incentive plans.

Management's large equity rewards are not guaranteed. Executives cannot realize the value of these awards if shareholders don’t benefit from considerable stock appreciation. At current prices, major performance awards remain far out of the money.

This creates a favorable incentive structure. Management is rewarded not simply for remaining employed, but for increasing the value of the business and the stock. Management and directors have strong financial incentives to create long-term stockholder value.

IVFH has extremely concentrated ownership. Insiders own 46.9% of the company. The major shareholders include James Pappas (19.1%), Bandera (11.3%), the Denver Smith group (9.0%), Intelligent Fanatics (6.6%), and Harper (5.2%). A small group of investors effectively controls the company and has major influence over key decisions.

Valuation:

I think the current $0.29 price reflects the worst-case scenario. The market capitalization is $15 million, and the enterprise value is $14.5 million.

If valuation multiples revert closer to earlier levels. The stock could be worth substantially more. The current EV/Revenue multiple is 0.30x. A return to 0.50x implies a value of about $0.63 per share. The current EV/EBITDA multiple is 6.59x. A return to 15x implies about $0.61 per share. The current EV/EBIT multiple is 9.23x. A return to 20x would mean about $0.58 per share. Together, these methods suggest a base-case value range of $0.60 per share.

These represent base-case valuations in the $0.58- $ 0.63-per-share range. If the company resumes growth, adds more vendors, and improves profitability, a share price of more than $1.00 is achievable.

IVFH is profitable, with an improved balance sheet, customer lists, and trade names/domains.

Conclusion

IVFH is a speculative turnaround. The stock trades at depressed prices after major operational and management changes. The company exited low-quality revenue. And sold non-core assets, strengthened its balance sheet, improved margins, and was profitable despite a large revenue decline. Now management must focus on consistent sales, modernize systems, improve onboarding, and reduce its dependence on a few large customers.

The bull case ultimately comes down to execution. If revenue stabilizes and management successfully scales its high-margin, asset-light platform, the current valuation is below the company's earnings potential. The company's ownership, activist-influenced board, and executive incentives are positive for shareholders.

Investors must realize the substantial risks. Customer concentration is high, liquidity is tight, and turnaround is unproven. Failure to stabilize revenue could push the stock closer to tangible book value. Successful execution will push the share price higher. For speculative investors, IVFH offers an asymmetric opportunity.

Long IVFH

PetMeds (PETS): The Hidden Cost Cutting Opportunities That Could Drive a Return to Profitability

PetMed's market price has been hit hard by declining revenue. Revenue fell from $227 million in FY2025 to $179 million in FY2026. The stock trades as if survival is in question.

Now the question is how PetMeds can become profitable again. During the recent earnings call, management announced that they saved about $6.1 million a year. That is not enough. Material additional savings exist if management aggressively right-sizes the business.

Management has already taken steps to improve efficiency and reduce costs. The company has reorganized its pharmacy, call center, and distribution operations. Headcount was reduced, and existing underperforming vendor relationships ended. Furthermore, they implemented a new ERP system, a new call center platform, and a fraud-prevention system. Together, it's expected to generate approximately $6.1 million in annualized cost savings.

Let’s examine the remaining opportunities for meaningful cost savings.

Consolidate to One Distribution Center

This may be the largest hidden opportunity. PetMeds currently operates two pharmacy and distribution facilities. One in Delray Beach, Florida, and Lynbrook, New York, versus annual revenues of $179 million. It might not be economical to have two warehouses, pharmacies, and duplicate inventory. Consolidating operations will lower facility expenses, utilities, rent, and property costs. Savings would also include warehouse payroll and inventory carrying costs. Estimated annual savings could be $2 million to $4 million. The main risk is that the New York pharmacy license may have strategic value. This consolidation could negatively impact delivery times for Northeast customers. The estimated savings are not supported by any direct evidence from management.

Call Center Automation

PetMeds mentions investments in AI, automation, call center technology, and digital customer service. Customer service remains a significant operating expense. Routine order inquiries, such as prescription refills, shipping, and autoship, can be automated. A 10% to 20% reduction in customer service staffing could generate annual savings of 1 to 2 million. The savings are primarily due to reduced headcount is reasonable but not proven.

Corporate Overhead

PetMeds currently employs approximately 189 people while generating $179 million in annual revenue. The company has also experienced significant executive turnover. Currently operating with an interim CEO and interim CFO. PetMeds still has opportunities to streamline its corporate structure. Human resources, finance, legal, compliance, and marketing could all gain efficiency. Estimated annual savings are $1 million to $3 million. The saving thesis is reasonable, but not directly supported by company disclosures.

Marketing Efficiency

Management has stated that it is shifting marketing spending. Advertising expenses totaled approximately $5.8 million in the fourth quarter. And roughly $23 million annually. Even a modest 10% reduction in advertising costs could save more than $2 million a year.

Eliminate Low Margin Categories

Management disclosed a failed wholesale initiative. The $2.1 million inventory write-off indicates expanding into low margin items. Potential candidates include low-margin foods, bulky products, and slow-moving inventory. A focused SKU program could reduce inventory levels and lower working capital requirements. EBIT improvement is possible in the estimated range of $0.5 million to $2 million. This is hard to prove quantitatively because the evidence for the savings is indirect.

Procurement and Supplier Rebates

According to the 10-K, 88% of PetMeds' inventory purchases come from ten suppliers. This level of supplier concentration provides meaningful negotiating leverage. Potential opportunities include securing better supplier rebates, improved payment terms, and volume discounts. Even modest improvements in procurement costs could have a significant impact on profitability. The estimated annual savings are $1 million to $3 million; the estimate is speculative.

Public Company Costs

PetMeds is a NASDAQ-listed company with a market capitalization of  $35 million. Expenses include audits, SEC compliance, legal fees, board compensation, and investor relations. Management has also highlighted elevated professional fees during the past year. If PetMeds were acquired by an outside party. Many of these costs could be eliminated immediately. Estimated annual savings are $2 million to $4 million. It's for the reasons a strategic buyer might pay a premium.

The opportunity for additional cost savings appears significant. Distribution consolidation could generate $2 million to $4 million annually. Call center automation may contribute another $1 million to $2 million. Streamlining corporate overhead could save $1 million to $3 million. And marketing optimization may provide an additional $1 million to $2 million. SKU rationalization could improve EBIT by $0.5-$2 million. Supplier negotiations may add another $1 million to $3 million. In total, these initiatives could yield an annual profit improvement of approximately $6.5 million to $16 million.

Can PETS Reach a Positive EBITDA?

Based on FY2026 results, PetMeds reported revenue of $179 million and a net loss of $57.3 million. Adjusted EBITDA in the fourth quarter was approximately negative $2.8 million. Annualizing suggests the business is currently operating at roughly negative $10 million to negative $12 million of EBITDA.

So, additional cost reductions of $6 million to $10 million could potentially move the company into a positive EBITDA of $2 million to $8 million.

If revenue stays around current levels and management executes the announced and additional cost-saving measures. PetMeds could generate positive EBITDA of $5 million to $12 million without returning to the $227 million revenue level it reached a year ago.

Conclusion

The $6.1 million savings number has hard evidence from management. THE OTHER SAVINGS ESTIMATES ARE ASSUMPTIONS, NOT COMPANY GUIDANCE!

Long PETS

The PetMeds (PETS) Board: Uniquely Qualified to Create Value Through a Turnaround or Acquisition

Analysis of the PetMeds Board

The PetMeds board of directors has proven expertise in strategy, operations, and capital allocation. This combination will support future shareholder value.

Peter Batushansky brings successful and proven industry experience. He founded and built Allivet. Allivet was one of PetMed's largest competitors before Batushansky sold the business to Tractor Supply (TSCO) in 12/2024. He understands customer acquisition, prescription fulfillment, veterinary relationships, margins, and industry consolidation. Also, he knows what buyers look for in a pet pharmacy business. If PetMeds gets more acquisition offers. His experience will be invaluable.

James LaCamp is the audit chair and joined the board in October 2025. LaCamp, at 42, is still an active operating executive. He is currently the CFO at Skydio. Previously, he was CFO of Flock Safety, SVP of Finance at Coupa Software, and an audit partner at Deloitte. He has an accounting degree from Santa Clara University, an MBA from Wharton, and is a CPA. 

LaCamp was not recruited for his expertise in the pet industry. Instead, he brings deep experience in financial analysis, capital allocation, M&A, corporate strategy, and value creation. He will be another key director in evaluating a turnaround, a restructuring, a strategic review, or a company sale.

Justin Mennen has expertise in technology and digital retail. Since PetMeds competes against much larger online players such as Chewy and Amazon. His background is relevant. His skill set will be used as PETS improves its technology, customer retention, marketing efficiency, online conversion rates, and turnaround.

Leah Solivan is the founder of TaskRabbit. She brings together experience in entrepreneurship and a company sale. She built and sold a successful company to IKEA. She understands both value creation and value realization. Her background suggests an objective approach. If a turnaround offers the best return? She would likely support.

Leslie Campbell joined the board in 2018 and became the Chair in January 2024. She accepted the role as Interim CEO in August 2025. This was after the departures of both the CEO and CFO. Further, Campbell held senior roles at Oracle and Dell. Her expertise is in finance, technology, governance, and board oversight.

Campbell is not an activist investor or turnaround specialist. But several factors make her more open to strategic alternatives than prior management. She purchased 60,000 shares in the open market in late 2024. Her career has focused on governance and shareholder oversight rather than empire building. This could make her more open to a transaction.

The recent leadership change as an Interim CEO may create an opportunity for the board to reassess strategy. The company still possesses valuable assets, a recognized brand, pharmacy licenses, and a large customer base with recurring autoship revenue. These attributes could make it attractive to strategic buyers.

Although the board recently declined two acquisition offers in 12/2025, Campbell's priorities as Interim CEO are likely to be stabilizing operations and recruiting permanent executive leadership. The most probable outcome is that the board will first attempt to improve performance while continuing to review all strategic alternatives, as publicly stated in the most recent quarterly results.

Conclusion

The board is uniquely strong for a company of PetMeds' size. Batushansky provides proven direct competitor expertise, backed by hands on operations and company sales. LaCamp contributes financial and strategic discipline. Mennen adds technology and digital commerce experience. And Solivan brings entrepreneurship and M&A knowledge. This is combined with Interm CEO Campbell's background in governance. The board appears built to evaluate a wide range of options.

Additional information on valuation. 

As mentioned earlier, board member Peter Batushansky founded, built, and sold Allivet. He sold it to TSCO in 12/2024 for 135M. Because Allivet was privately owned. Its financial results were not publicly disclosed. But we can attempt to make estimates based on what is known about the transaction.

Tractor Supply (TSCO) bought Allivet for $135 million in cash. Further, TSCO said in a press release following its announcement of the purchase of Allivet. Allivet could generate $1 billion in revenue at full scale. However, it's based on future potential. Allivet served pet owners online as a licensed online pet pharmacy for over 30 years. The exact same businesses as PETS, with headquarters in Florida.

Using the $135M Allivet's sale price. What was Allivet's estimated annual revenue? Pet pharmacies and e-commerce businesses are often bought for 0.5x to 1.5x revenue, or 8x to 15x EBITDA. A valuation of 0.75x revenue means annual sales of $180 million, and 1.0x revenue means $135 million.

Based on these valuation ranges, Allivet's estimated annual revenue is between $100 million and $200 million. Allivet’s annual revenue for 2024 is likely to be less than PETS’ $189M trailing 12 months of revenue. This is an estimate based on acquisition multiples, not a public figure.

The key takeaway is that Allivet appears profitable enough for Tractor Supply to pay $135 million for it. In contrast, PetMed is currently losing money and burning cash. That profitability difference likely explains the valuation gap between the two companies.

PetMeds investors should focus on whether the company can return to profitability. If PetMeds could eliminate its losses and generate $10–15 million annually. PETS could support a valuation closer to Tractor Supply's Allivet. PETS has a market cap of 35M, and owns 35M in Florida real estate with 185M in TTM sales. In theory, if PETS becomes profitable, its market value should be several times higher. However, if losses continue and cash burn persists, the comparison to Allivet isn't meaningful.

Long PETS

PetMed Express (PETS): High-Risk Turnaround, Hidden Assets, Activism

PetMed Express (PETS) is a declining pet pharmacy and pet healthcare company. The current market valuation fails to account for several factors. Such as cash, real estate, prior acquisition interest, and signs of turnaround efforts. Two prior acquisition bids were $4-4.25 per share. Yes, revenue and margins were declining. And the share price has fallen. Further, concerns have increased due to competition. The current valuation suggests investors are forecasting a significant deterioration in the franchise. Execution risk is substantial. Although the existing assets provide material downside support. Continued operating losses will quickly reduce the margin of safety.

The current valuation suggests investors are pricing in a significant deterioration in the franchise value. Any meaningful improvement will create material upside in the stock price. Ultimately, the investment case depends less on asset values. But on whether management can stabilize revenue and translate operational improvements into earnings.

PETS lacks a permanent CEO. Or an interim CEO with experience in the pet pharmacy industry. Leadership stability is critical to turnarounds. An interim CEO makes for additional activist or new acquisition talks. Interim leadership might emphasize immediate value realization over long-term transformation.

Risks:

According to the latest 10Q, revenue fell 22.7%, and reorder sales declined 22.6%. Operating cash flow was –$23.7M. The $26.7M in goodwill was fully impaired due to lower forecasts and a declining market value. The $2.1M inventory write-down indicates operational errors. With interim leadership, it's hard to turn a company around.

PETS is a high-risk turnaround. The business is shrinking. Although the balance sheet provides time. The stock trades at around $2.20, with a market cap of $46M and an enterprise value of $19.22M. Latest data show cash fell from the prior-year balance of $ 54.72M to $26.9M due to negative operating cash flow.

Additional risks include permanent customer losses to competitors such as Chewy and Amazon. And failure to successfully integrate PetCareRx, continued cash burn, lack of permanent leadership, margin pressure from pricing competition and discounting, and possible further impairment of brand value

Opportunities:

PETS is mostly an asset backed special situation.

Management initiatives include cost reductions, PetCareRx integration, autoship expansion, digital improvements, and veterinary offerings.

The market price ignores the values of owned assets. PETS has $26.9M in cash, $12.2M in inventory, $1.6M in accounts receivable, $27.6M in property and equipment, and $32.8M in shareholder equity. Liabilities consist of normal operating costs rather than debt obligations. Investors are overlooking asset values that exceed GAAP.

The company owns its 14.60-acre Delray Beach, Florida headquarters and distribution facility, along with 2 acres of excess land. Based on comparable South Florida industrial and commercial property values. The Delray property may be worth approximately $35M. Although the exact market value is uncertain. This creates potential upside with a sale-leaseback or renewed outside interest.

For the nine months ended December 31, 2025, PETS generated $136.2 million in sales. Reorder sales were $112.7 million, representing approximately 83% of total sales. New order sales were $18.6 million, while membership fees contributed $4.9 million. The revenue continues to come from existing and repeat customers.

Additional assets include the PetMeds brand and PetCareRx trade name. And internet domains, toll-free customer assets, and a $5.3M investment in Vetster. Additionally, management reduced costs and inventory by integrating PetCareRx. Digital operations are improving, and Telehealth is expanding. Inventory dropped from $16.2M to $12.2M. When an asset-heavy company trades below its estimated private value. Strategic outcomes, such as the sale of the company, increase.

Activist/acquisition

SilverCape announced in December 2025 that it would take PETS private for $4.00 a share. And changed its 13G status to 13D, making it the largest outside investor. They increased their ownership stake to 12.20% (2,579,696 shares). Management stepped up and used a poison pill to prevent SilverCape from acquiring more than 13% of the outstanding shares.  Soon after, Cardone Ventures submitted a cash offer of 4.25. Cardone mentioned the value of the PETS brand. Including its customer relationships, pharmacy platform, and operating infrastructure. Other major value investors have also acquired positions. Nina Capital owns about 8.8% and has added to its position through open-market purchases. Pinnacle Value Fund acquired a position in 2025 at an average price of $2.84 per share. As of February 2026, Diveroli Investment Group owned 391,757 shares, equal to roughly 1.83% of PETS.

There is also reason to believe that acquisition discussion may still be possible. SilverCape's proposal said it would "engage constructively" with the Board and management. Furthermore, neither management nor SilverCape publicly stated that negotiations or discussions had ended. Because SilverCape still owns over 12% of the company, strategic discussions cannot be ruled out. Although there is no public evidence that negotiations continue. We shouldn't discount the possibility of PETS going private.

Sum of the parts valuation

Valuation Ratios

With any hint of turnaround success, the valuation will increase substantially.

Additional reasons for a higher valuation:

Reorder sales are 83% of total sales. PETS still owns customer relationships and brands. There is no debt burden, although its operating liabilities are large. And the Delray property may be worth over 40M.

The margin of safety is supported by cash, real estate, customer assets, and a minority investment in Vetster. Significant upside still may depend on management stabilizing operations and converting repeat customers into sustainable profits.

Conclusion:

PETS is more of an asset-backed special situation than an operational turnaround. As I said, PETS has declining revenue, competitive pressure, large cash burn, and leadership uncertainty. The assets are not reflected in the current market price.

Prior acquisition offers of $4.00–$4.25 per share suggest that value exists beyond earnings power. Liquidation value has less impact on the investment. But instead, focus more on whether management can stabilize operations. And convert its large base of repeat customers into profitability. If the turnaround gains traction or strategic alternatives emerge, the upside could be substantially higher prices. But if operating losses continue, the safety margin shrinks. For investors comfortable with high risk, I believe PETS may offer asymmetric risk/reward for speculative investors.

Long PETS

Precision Optics (POCI): A High Risk, Potential High Reward Microcap Transition Story

Precision Optics is transforming from a niche engineering supplier to a large manufacturer. If management executes effectively. This transition could drive outsized earnings growth and a higher stock price.

Precision Optics makes specialized devices and lighting components used in the medical market. It also provides custom optical components for industrial, defense, and aerospace applications. Precision Optics offers design, prototyping, regulatory support, and manufacturing. Founded in 1982 and based in Massachusetts, with operations in Maine and Texas. Precision Optics (POCI) uplisted to the Nasdaq in 2022. At the time, management said their goal was to improve visibility, increase institutional sponsorship, and improve liquidity.

The recent $10M public stock offer at $3.60 was oversubscribed. Investors included existing shareholders and new value institutional investors. Further, the CEO, CFO, COO, and directors bought shares in the recent offering at the same terms as outside investors.

Now the question for investors. Can POCI transform from a thinly traded microcap into a small med tech growth company?

The transformation is becoming more visible when looking at the prior 3 quarters. Q1 2026 revenue was 6.70M, Q2 2026 was 7.4 M, and the most recent reported Q3 2026 was 8.70M. Gross margins also had a major recovery, from 14.40% in Q1, 2.80% in Q2, and 24% in the most recent Q3 2026. Adjusted EBITDA went from negative to positive in Q3 2026.

Risks:

Execution remains the largest risk and is discussed during conference calls. Management highlighted low yields, scrap costs, labor inefficiencies, and training challenges. Gross margins fell to 2.8% in Q2, and EBITDA guidance shifted from a projected profit to a meaningful loss. This suggests management underestimated the difficulty of scaling.

Customer concentration remains significant. A large portion of revenue depends on a small number of customers. During Q3, an aerospace customer requested a temporary production slowdown. This shows how results can change if a key customer delays or reduces orders. While recent financing has improved liquidity, dilution risk has not disappeared. And capital may be needed if profitability takes longer than expected. POCI is a small manufacturer. It is struggling to prove it can convert revenue growth into sustainable earnings

Opportunities:

Precision Optics is transitioning from a small engineering company to a production manufacturer. Potentially creating attractive operating leverage.

Management stated that we are operating at a record level on the latest Q3 2026 conference call. This was evident as revenue increased from $6.7 million in Q1, $7.4 million in Q2, and to a record $8.7 million in Q3 2026.

POCI's aerospace business may be a valuable hidden asset. Its satellite-related programs generate roughly $3.6 million in quarterly revenue. And production yields are improving to 97%. This implies an annual revenue run rate of $14-15 million for a single customer. In addition to aerospace, the company supports attractive medical markets. Such as cystoscopes, ophthalmic devices, arthroscopy, urology, and otoscopy. Management says these segments are growing at mid to high-teen annual rates. Furthermore, medical products create sticky customer relationships. Because of their long product life cycles and regulatory barriers. Also, the recent $10 million financing reduces near term financial risk.

Valuation Metrics: 

Comparison to Peers

POCI = 52 Week price change = 6.43%,current ratio = 2.10, book value 2.10, revenue per share = 3.10,quarterly revenue growth (yoy) =  108.00%

Management's technical background and shareholder alignment provide a foundation as the company moves from a niche engineering business into a larger manufacturing operation. From 2006 to 2011, the CEO was the company's Executive Vice President and Chief Scientific Officer. He earned a PhD in Applied Physics from Princeton University, and he holds an MA in Mechanical/Aerospace Engineering. He's an optical and imaging guy, so his background makes sense.

Cataylst:

Management must move beyond simply using its proprietary micro optics and imaging technologies to provide services and develop new products. And successfully transition to profitable large scale manufacturing. When higher production volumes convert into consistent earnings and cash flow. The market will value it more as a growing medical technology manufacturer. Continued institutional interest will increase visibility and reduce the discount on microcap stocks.

I started with a long position in POCI. POCI is a high risk idea. But I would recommend POCI as a speculative investment.

Long POCI

Debt Free Operational Reset, Innovative Food Holdings IVFH

 
Innovative Food Holdings (IVFH) is a nanocap specialty food distributor undergoing a more focused asset-light model. Shares trade at $0.82 with 54.8 million shares outstanding and a market value of $44.9 million. Public float is 28.7 million shares or 23.5 million.

By selling their Pennsylvania warehouse and closing the unprofitable cheese business in 2025, management proved they can make difficult pro-shareholder decisions. Eliminating the Pennsylvania warehouse will yield quarterly savings of approximately $200,000 in interest, while closing the unprofitable cheese business will enhance gross margins.Further, management is growing the Digital Channels business, which adds more products and vendors without inventory. Their use of AI helps accelerates onboarding,jumping from 13 items historically to 400 items added in just four weeks. Meanwhile, the airline catering segment grew 26% year-on-year.

A debt-free balance sheet, margin recovery, a scalable platform, and multiple expansions create a higher stock price.

Business Overview:
Innovative Food Holdings (IVFH) distributes specialty foods through an asset-light digital network (Sysco, US Foods, Amazon) and a fast-growing airline catering arm (+26% YoY, Q2 2025). Recent acquisitions (Golden Organics, LoCo) have expanded regional capacity and fed into its digital catalog. Meanwhile, the airline business is consolidated in Chicago for efficiency.

Recent Developments (Q2 2025)
IVFH posted $21.1M revenue (+27% YoY) with airline catering up 26% and Amazon triple-digit growth; the remaining improved sequentially. Reported gross margin was 21% but ex-cheese margin expanded by 66 bps. OCF turned positive (+$575K vs. -$977K in Q1), net income swung to $59K, and the cheese exit plus the pending PA warehouse sale (Sept. 2025) set up lean, higher-margin operations.

Catalyst:
The following two quarters, ~$9M of debt is retired by Q4 2025, reducing ~$200K/quarter in interest expense and leaving IVFH nearly debt-free. The exit from the unprofitable cheese business removes a structural drag, while the Chicago consolidation unlocks SG&A leverage and pushes margins toward the mid-20s. At the same time, AI-driven catalog expansion accelerates growth, with onboarding speed cut by ~80% and thousands of high-margin SKUs ready to launch. Airline catering continues to compound (+26% YoY) with embedded recurring revenue and ongoing customer wins adding upside. With valuation at just 0.66× EV/Sales-well below peers at 1-2×-and normalized EBITDA power set to re-rate sharply, the timing offers investors a rare window before cleaner results and balance sheet optics force the market to close the gap.

Ownership
Activist shareholders with skin in the game on the board is a game changer.Innovative Food Holdings has unusually aligned ownership for a turnaround.

Pappas owns 18% of the company's shares and has been on the board since 2020. His background in restaurants and distribution makes IVFH an easy fit for his playbook. He's a proponent of "growth activism" - fixing capital structures, installing operators, and aligning governance with customers.
 

Bandera Partners holds ~12% and Denver Johnson Smith ~9%. Inlight Wealth (~5%) and Intelligent Fanatics (~5.5%) add to the institutional sponsorship. Collectively, these funds control >45% of equity. Insider alignment is meaningful: CEO Bill Bennett owns ~4.5%, COO Brady Smallwood holds option grants based on performance, and director Hank Cohn retains ~5%. The result is a concentrated, shareholder-friendly register where activists and management align economically. Active ownership is critical. The company misallocated and devalued assets for years. It anchors capital discipline, enforces board refreshment, and supports operating playbooks built for growth. Large value-oriented shareholders directly impact strategy and capital allocation. Value-based activist ownership will guide improved capital allocations, forcing a clear path to create long-term value.

Valuation:
At just 0.66× EV/Sales, IVFH trades at a steep discount to distribution peers Sysco (1.0×), US Foods (0.9×), and Performance Food Group (0.8×). A re-rating to 1.0× implies ~50% upside. At $0.82/share, IVFH offers material upside with multiple opportunities to accelerate growth and margin expansion.

Risks:
Margin and growth risks include accelerated catalog growth and recent acquisition integrations. Customer concentration remains a factor, with U.S. Foods still representing a large distribution channel and subject to competitive pressure. As a thinly traded small-cap, IVFH shares carry liquidity, risk and volatility. Finally, the expected synergies from the Denver acquisition have not yet been proven, leaving room for integration challenges if management falls short.

Conclusion:
IVFH is an overlooked micro-cap entering a turnaround phase. Multiple catalysts, including debt elimination, AI-driven catalog expansion, airline catering growth, and margin recovery, are set to re-rate the valuation. At just 0.66× EV/Sales, the stock trades well below its peers despite intrinsic value estimates pointing to 2-3× upside. A small, ignored company undergoing a balance sheet and operating reset, where execution through Q4 2025 and after creates potential for asymmetric returns.

Long:IVFH 

Tandy Leather TLF: Dear Chairman

 Today's post updates the risks and opportunities associated with the recent real estate sale and also contains a message for the Chairman of the board.

Business Summary:

• Tandy Leather (TLF), founded in 1919, is the profitable leader of the leather crafting retail market. 

• TLF sells leather and leather craft-related items primarily through retail stores, websites, or direct account representatives. 

• Tandy has 101 stores in 40 states, six provinces in Canada, and one store in Spain. 
• Several smaller, privately family owned competitors exist, including Double Eagle Leathersmith, Montana Leather Company, and Weaver Leather Supply.

Tandy Leather announced on Dec 6th that its corporate headquarters was sold for $26.5 million before taxes/expenses. The expected closing date is sometime in January 2025. As part of its transition to new facilities in Fort Worth, Texas, Tandy will lease back the facilities until September 2025.

The announcement had a minimal impact on TLF's stock price. Before the announcement, the stock traded at approximately $4.20 per share over the trailing three months. Following the sale announcement, the price rose modestly to $4.75 per share. Given the stock’s limited trading volume, even this increase lacked significant momentum.

This muted market reaction is surprising, especially considering that the company’s liquidation value, by my conservative estimate, increased by 42%. This estimate assumes $15 million in additional net cash proceeds from the sale, based on a pre-announcement value of $35 million. My calculation factors in estimated real estate taxes and expenses of $11.5 million, leaving $15 million in net cash proceeds.

 

Dear Mr. Chairman,

I have been a dedicated shareholder of Tandy for many years, but I am increasingly concerned about the board’s operational oversight and strategic decision-making. My concerns stem from significant missteps, including the mishandling of inventory errors and the substantial expenditure on consultants, which squandered shareholder value.

The current CEO is 63 years old, and two CFOs have been hired and departed within two years. This instability raises serious questions about the board’s ability to identify and retain competent leadership for key positions. Why should shareholders trust the board to effectively replace a future CEO or CFO? Furthermore, how does the board intend to responsibly allocate proceeds from the headquarters sale, valued at $26.5 million?

Accountability for Inventory Errors
I believe the removal of former CFO Ms. Castillo following the discovery of inventory errors in Q4 2019 was a mistake. Despite this, the board has not taken accountability for the multi-year inventory errors or the lack of compliant systems that led to them. As a fiduciary body, the board is responsible for overseeing inventory management, ensuring system compliance, and approving budgets for improvements. Yet, the company relied on outdated, non-integrated systems—some stores even maintained paper records. These shortcomings culminated in regulatory penalties and significant value destruction, further eroding shareholder trust.

Financial Oversight Gaps
Since 2020, Tandy has recruited and lost two CFOs. These hires were ill-suited for the role, as evidenced by their short tenures. This reflects a glaring gap on the board—a lack of members with real-world corporate finance and operational experience. This deficiency has directly contributed to ongoing accounting irregularities. Why was Ms. Castillo removed in the first place, and how can shareholders trust the board to effectively select a new CFO given its track record?

Compensation Discrepancies and Shareholder Concerns
In FY 2023, Tandy, a $35 million nano-cap company, paid its CEO and a board member $1,181,280 in total compensation. The CEO now holds 439,285 shares, or 5.22% of shares outstanding, alongside generous annual stock options—such as 92,000 shares in 2022 with an exercise price of $3.52. These figures appear disproportionate to Tandy’s size and performance, particularly in light of the challenges faced since the discovery of inventory errors.

Cash Balance Decline and Cost Mismanagement
When inventory errors were identified in Q4 2019, Tandy’s audited cash balance stood at $25 million. By September 2022, when Tandy was relisted on NASDAQ, this had plummeted to $3 million. While inventory valuation issues did not impact cash directly, the precipitous decline reflects significant mismanagement. Currently, the cash balance sits at $10 million. What specific actions contributed to this erosion of cash reserves?

From 2019 to 2020, the company spent $5.5 million on restatement efforts and CFO transitions. Over two years, an additional $4.9 million was allocated to restatements, with $594,000 earmarked for CFO-related expenses, as disclosed in the 10-K. Despite these investments, the board failed to ensure the implementation of effective ERP and accounting systems, leading to ongoing inefficiencies and delays.

Relisting and Additional Costs
Tandy was delisted from NASDAQ in August 2020 after the board failed to prepare timely financial statements. It took nearly two years—and significant costs for financial consultants, ERP system advisors, and CFO transitions—for the company to regain its listing in July 2022. Between 2019 and 2022, millions of dollars were spent without clear disclosure of consultant costs, further frustrating shareholders.

The board must address these systemic failures and communicate a transparent plan for the future. As a shareholder, I urge you to take immediate action to restore confidence by improving oversight, ensuring accountability, and demonstrating a commitment to responsible financial stewardship.

 

Shareholders are not unreasonable in believing the upcoming cash infusion will evaporate. Furthermore, the proposed small dividend would do little to offer meaningful liquidity to long-term shareholders who have patiently supported the company for years.

 

Opportunities

The board must recognize that Tandy Leather Factory (TLF) is not suited to remain a publicly listed company. However, due to inertia, the company continues to bear unnecessary administrative and operational expenses, which serve no real benefit to shareholders or employees. A strategic sale of Tandy would unlock significant value and position the company for long-term health and growth under more suitable ownership.

Tandy's future lies with an entity capable of nurturing its potential for the benefit of all stakeholders. Based on NAV or EBITDA multiple valuations, Tandy could command a premium of over 65% above its current market value.

A new owner could realize over $1 million in annual savings by eliminating public company costs, including listing fees, audits, and legal expenses. These savings alone would contribute to immediate profitability improvements.

Since 2018, Tandy's EBITDA margins have averaged approximately 6.75%, generating an annual EBITDA of $5.4 million. However, for the 17 years prior, EBITDA margins averaged a much stronger 12.6%. If a new owner can drive modest revenue growth—boosting the current $76 million average revenue to $80 million—and restore historical EBITDA margins to 12%, Tandy’s annual EBITDA could reach $10 million.

This approach not only enhances operational efficiency but also provides a sustainable foundation for growth, benefiting employees, customers, and investors alike. The path forward is clear: a strategic sale would unlock Tandy's true value and secure its future.

 

Valuation using the Balance Sheet

These metrics all point to a much higher valuation over the current 38M.

Conclusion: NOW is the time to explore strategic alternatives.

 

I respectfully urge the Board of Directors to engage in a thorough review of strategic alternatives, including the potential sale of the company, to maximize shareholder value and ensure the long-term interests of all stakeholders are prioritized

The board must urgently develop and present a transparent plan to ensure shareholders have the opportunity to exit at a fair and reasonable price – no less than $7 per share. If the board cannot achieve this without pursuing a sale of the company, then it is imperative they explore and initiate a formal sale process without delay.

As Benjamin Graham wisely noted in Security Analysis:

"It is not the function of the corporation to make the market for its shares, but it should provide a fair and reasonable opportunity for stockholders who desire to dispose of their holdings to obtain an adequate price for them."

Currently, minority shareholders are being neglected and undervalued by Tandy’s board. This has persisted for far too long. Mr. Chairman, it is time to demonstrate goodwill and take meaningful action to address shareholder concerns.

 

Long TLF